Susanna Chau
Director/Board Member presso National Investor Relations Institute (Silicon Valley)
Profilo
Ms. Susanna Chau is a Manager-Investor Relations at Astex Pharmaceuticals, Inc. and Head-Investor Relations at Coherus BioSciences, Inc. Ms. Chau was previously employed as a Manager-Investor Relations by SuperGen, Inc.
Posizioni attive di Susanna Chau
| Società | Posizione | Inizio |
|---|---|---|
Astex Pharmaceuticals, Inc.
 Astex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Astex Pharmaceuticals, Inc. researches and develops oncology drugs. It is dedicated to the discovery, development, and commercialization of novel therapeutics with a focus on cancer. Its products include Guadecitabine, Onalespib, AT7519, AT13148, ASTX727, ASTX660. The company was founded on May 28, 1997 and is headquartered in Pleasanton, CA. | Investor Relations Contact | 21/09/2011 |
National Investor Relations Institute (Silicon Valley)
 National Investor Relations Institute (Silicon Valley) Miscellaneous Commercial ServicesCommercial Services National Investor Relations (IR) Institute operates as an association for investor relations professionals. It offers IR education, mentoring, and networking. The company is headquartered in Belmont, CA. | Director/Board Member | 06/08/2018 |
Precedenti posizioni note di Susanna Chau
| Società | Posizione | Fine |
|---|---|---|
SuperGen, Inc.
 SuperGen, Inc. Pharmaceuticals: MajorHealth Technology SuperGen, Inc. researches and develops drugs, diagnostics and other therapeutic products. It discovers and develops novel cancer therapies and drugs. SuperGen buys rights to drugs in advanced stages of development and bring them to market. The company's major product is Nipent it is used for graft-versus-host disease, which afflicts bone marrow transplant recipients and various forms of lymphoma. SuperGen also makes a few generic cancer drugs like paclitaxel. The company was founded on March 6, 1991 by David M Fineman and Elliott L. Fineman and is headquartered in Dublin, CA. | Investor Relations Contact | 13/09/2011 |
| COHERUS BIOSCIENCES, INC. | Investor Relations Contact | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| COHERUS BIOSCIENCES, INC. | Health Technology |
| Aziende private | 3 |
|---|---|
SuperGen, Inc.
SuperGen, Inc. Pharmaceuticals: MajorHealth Technology SuperGen, Inc. researches and develops drugs, diagnostics and other therapeutic products. It discovers and develops novel cancer therapies and drugs. SuperGen buys rights to drugs in advanced stages of development and bring them to market. The company's major product is Nipent it is used for graft-versus-host disease, which afflicts bone marrow transplant recipients and various forms of lymphoma. SuperGen also makes a few generic cancer drugs like paclitaxel. The company was founded on March 6, 1991 by David M Fineman and Elliott L. Fineman and is headquartered in Dublin, CA. | Health Technology |
National Investor Relations Institute (Silicon Valley)
National Investor Relations Institute (Silicon Valley) Miscellaneous Commercial ServicesCommercial Services National Investor Relations (IR) Institute operates as an association for investor relations professionals. It offers IR education, mentoring, and networking. The company is headquartered in Belmont, CA. | Commercial Services |
Astex Pharmaceuticals, Inc.
Astex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Astex Pharmaceuticals, Inc. researches and develops oncology drugs. It is dedicated to the discovery, development, and commercialization of novel therapeutics with a focus on cancer. Its products include Guadecitabine, Onalespib, AT7519, AT13148, ASTX727, ASTX660. The company was founded on May 28, 1997 and is headquartered in Pleasanton, CA. | Health Technology |
- Borsa valori
- Insiders
- Susanna Chau
